Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06230757 · ClinicalTrials.gov registry record · Phase 2
Psilocybin for Treatment-Resistant Depression
A Phase 2 study of Major Depressive Disorder and Treatment-Resistant Depression, sponsored by University of Colorado, Denver.
- Active
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06230757 is a Phase 2 study of Major Depressive Disorder and Treatment-Resistant Depression that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 40 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06230757, a Phase 2 study of Major Depressive Disorder and Treatment-Resistant Depression, is active but no longer recruiting, sponsored by University of Colorado, Denver.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the efficacy of psilocybin on the symptom of anhedonia in individuals with treatment-resistant major depressive disorder.
Conditions Studied
Interventions
- DRUG Psilocybin 25mg
- DRUG Placebo (active placebo)
Study Locations (1)
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-07-08 |
| Est. Completion | 2026-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06230757
The ClinicalTrials.gov registry entry for NCT06230757 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (89% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Psilocybin 25mg is the first listed.
NCT06230757 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT06230757 about?
NCT06230757 is a clinical study titled "Psilocybin for Treatment-Resistant Depression". The purpose of this study is to evaluate the efficacy of psilocybin on the symptom of anhedonia in individuals with treatment-resistant major depressive disorder.
What is the current status of trial NCT06230757?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2024-07-08. Estimated completion is 2026-03-01.
What conditions does trial NCT06230757 study?
This clinical trial studies the following conditions: Major Depressive Disorder, Treatment-Resistant Depression, Anhedonia.
What interventions are being tested in trial NCT06230757?
The interventions under investigation include: Psilocybin 25mg (DRUG), Placebo (active placebo) (DRUG).
Who is sponsoring clinical trial NCT06230757?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06230757 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
RECRUITING · Phase 2
-
Study of ALTO-300 in MDD
RECRUITING · Phase 2
-
Regulation of Affect and Physiology in Depression
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
RECRUITING · Phase 2
-
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.